2021 will be a banner year for technology stocks.
Mark my words. The biggest fortunes this year won’t be found with commodities or gold. They will be made with tech stocks. And my mission is to deliver these life-changing returns to my readers.
After all, we are living in an age of rapid technological development that has brought us explosive trends like 5G wireless technology, artificial intelligence (AI), and the next wave of sustainable energy production. These are the technologies that are eliminating scarcity and creating a world of abundance right before our eyes.
And for serious tech investors, there’s one specific area of technology that needs to be on your radar…
The Biggest Breakthrough Since Antibiotics
We’re on the cusp of a complete reordering of health care… and at the very beginning of a major bull run in biotech.
It all has to do with an emerging technology trend called precision medicine.
Let me explain…
These days, we typically wait until we feel sick before we seek medical treatment. Then, we visit a hospital, where our symptoms are treated with varying degrees of success.
Very often, each patient is treated with a “one size fits all” therapy. This approach to medicine is reactionary.
In the very near future, medicine will be proactive and personalized.
We will have our genome – our genetic “blueprint” – sequenced to identify mutations in our genetic code that lead to disease. Then, thanks to genetic editing technology, we’ll be able to fix these mutations – these “typos” – in our DNA.
You will be “cured” before you even feel sick.
And this future is close at hand…
Back in November 2019, I attended a biotechnology conference, the STAT Summit. There, I witnessed an incredible presentation by Vertex Pharmaceuticals (VRTX) CEO Jeffrey Leiden.
Vertex and CRISPR Therapeutics (CRSP) have been working together on a therapy for sickle cell disease and beta thalassemia. Bad mutations in the hemoglobin gene cause these blood disorders.
At that conference, Leiden said they had treated two patients at that point – one with sickle cell disease and the other with beta thalassemia.
And the results were phenomenal.
The beta thalassemia patient had not needed a blood transfusion in nine months. For context, patients with this disease typically need blood transfusions every 2–4 weeks. And the sickle cell patient had not suffered a crisis in four months.
That bears repeating. The patients were free from symptoms and blood transfusion-independent for months. That had never happened before.
And time has only strengthened the evidence…
Last year, close to the one-year anniversary of receiving the treatment, the sickle cell patient provided an update on her progress. The treatment had alleviated “virtually all the complications of her disorder.”
The CRISPR treatment has had similar long-term success with beta thalassemia. Within five months, a second beta thalassemia patient was also able to stop receiving blood transfusions.
And in the time since, several more patients have been added to the trials. The results continue to be excellent.
As of this past December, seven beta thalassemia patients had not needed a transfusion since receiving the treatment. And three sickle cell patients hadn’t had any crisis episodes after previously experiencing a median of seven a year. The first sickle cell patient was even able to discontinue the pain medications she’s needed for most of her life.
Forgive me for stating the obvious, but this is just incredible. This wasn’t a case of just an improvement or some demonstration of efficacy; the genetic therapy was a complete cure of their fatal conditions. That shows the power of CRISPR.
What does this mean for investors?
Major Bull Run
Investors need to pay close attention to biotech this year. We’re at the very beginning of a multiyear bull market for the biotech space.
I mean, just think about it…
We have a combination of advanced diagnostic technologies coupled with computer processing power, artificial intelligence, machine learning, and even quantum computing. And we have an incredible genetic editing technology called CRISPR.
We also saw $45.6 billion of private investment in the biotechnology sector in 2020. And we’re seeing a wave of IPOs as well…
As a result, we are going to have an explosion of therapies. There will also be a shorter time between drug discovery and FDA approval because of technologies like AI and machine learning.
We’re going to also have better-quality drugs that will have fewer side effects. And they will be highly personalized for each patient.
And once Wall Street sees this, what is it going to do?
It will invest more in that space because it finally understands what incredible technological advancements are happening.
It’s going to be like dumping fuel on a fire…
So pay close attention to the tech sector – especially biotech. Fortunes will be made by savvy investors.
And on Thursday, March 18, at 8 p.m. ET, I’d like to show you how to be one of them.
You see, thanks to a government agency, a small sector of the biotech market is getting ready to accelerate…
I call these tiny stocks “timed stocks” because they have a preset “timer” attached to their share prices.
And when that timer goes off, these timed stocks can skyrocket…
They can soar hundreds – or even thousands – of percent in weeks or just days.
And thanks to two particular forces, this opportunity is bigger than ever… and moving faster than ever before. These timed stocks have entered into a new “countdown” period, and I don’t want anyone to miss out.
That’s why, on Thursday, March 18, at 8 p.m. ET, I’m hosting a special event we’re calling Timed Stocks: Final Countdown. I’m going to show you how to identify timed stocks… and how to start profiting from them right away.
And be sure you mark your calendar: March 18 at 8 p.m. ET.
I hope to see you there.
Editor, The Bleeding Edge